John L Humm
Overview
Explore the profile of John L Humm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
3530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lafontaine D, Augensen F, Kesner A, Vincent R, Kirov A, Krebs S, et al.
EJNMMI Phys
. 2025 Mar;
12(1):22.
PMID: 40064717
Background: Prior to selective internal radiotherapy of liver tumors, a determination of the lung shunt fraction (LSF) is performed using 99mTc- macroaggregated albumin (99mTc-MAA) injected into the hepatic artery. Most...
2.
Mahajan S, Grkovski M, Staton K, Ravassa S, Domfe K, Strauss H, et al.
Clin Transl Imaging
. 2025 Feb;
12(6):619-627.
PMID: 39935517
Background: The small molecule radiotracer I-PU-H71 is an imaging biomarker of epichaperome formation. The tracer has been established to localize in tissues under chronic stress, specifically in cancer cells and...
3.
Gui C, Wray R, Schoder H, Deasy J, Grkovski M, Humm J, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2436407.
PMID: 39348119
Importance: Given high rates of locoregional control after definitive management of head and neck squamous cell carcinoma (HNSCC), better methods are needed to project distant metastasis (DM) risk. Tumor hypoxia...
4.
Lee N, Sherman E, Schoder H, Wray R, Boyle J, Singh B, et al.
J Clin Oncol
. 2024 Jan;
42(8):940-950.
PMID: 38241600
Purpose: Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)-related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could identify...
5.
Bodei L, Tuttle R, Grewal R, Mauguen A, Augensen F, Abusamra M, et al.
Eur J Nucl Med Mol Imaging
. 2023 Sep;
51(2):325-329.
PMID: 37712994
No abstract available.
6.
Grkovski M, ODonoghue J, Imber B, Andl G, Tu C, Lafontaine D, et al.
J Nucl Med
. 2023 Aug;
64(11):1779-1787.
PMID: 37652541
A single-institution prospective pilot clinical trial was performed to demonstrate the feasibility of combining [Lu]Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic body radiotherapy (SBRT) for the treatment of oligometastatic castration-sensitive prostate...
7.
Naydenov N, Teplov A, Zirakchian M, Ruan S, Chu B, Serencsits B, et al.
J Vasc Interv Radiol
. 2023 May;
34(9):1556-1564.e4.
PMID: 37201655
Purpose: To evaluate the yttrium-90 (Y) activity distribution in biopsy tissue samples of the treated liver to quantify the dose with higher spatial resolution than positron emission tomography (PET) for...
8.
Mauguen A, Grewal R, Augensen F, Abusamra M, Mahajan S, Jayaprakasam V, et al.
Eur J Nucl Med Mol Imaging
. 2023 May;
50(10):2971-2983.
PMID: 37171634
Purpose: To introduce a biomarker-based dosimetry method for the rational selection of a treatment activity for patients undergoing radioactive iodine I therapy (RAI) for metastatic differentiated thyroid cancer (mDTC) based...
9.
Tringale K, Wolden S, Karajannis M, Haque S, Pasquini L, Yildirim O, et al.
J Neurooncol
. 2023 Feb;
162(1):69-78.
PMID: 36853490
Purpose: Intraventricular compartmental radioimmunotherapy (cRIT) with 131-I-omburtamab is a potential therapy for recurrent primary brain tumors that can seed the thecal space. These patients often previously received external beam radiotherapy...
10.
Pandit-Taskar N, Grkovski M, Zanzonico P, Pentlow K, Modak S, Kramer K, et al.
J Nucl Med
. 2023 Feb;
64(6):946-950.
PMID: 36759197
Radiolabeled antibody treatment with I-omburtamab, administered intraventricularly into the cerebrospinal fluid (CSF) space, can deliver therapeutic absorbed doses to sites of leptomeningeal disease. Assessment of distribution and radiation dosimetry is...